![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » JURY RULES UNANIMOUSLY IN PFIZER'S FAVOR IN AMLODIPINE PATENT CASE
JURY RULES UNANIMOUSLY IN PFIZER'S FAVOR IN AMLODIPINE PATENT CASE
August 18, 2006
Pfizer Inc said that a federal court jury in the Eastern District of Virginia (Alexandria) has ruled unanimously that Pfizer does not infringe Synthon IP's U.S. patent covering a process for making amlodipine, the active ingredient in Norvasc. Norvasc is the world's most-prescribed branded medicine for treating hypertension.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=4817594)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct